论文部分内容阅读
目的探讨低分子肝素对尘肺肺心病患者血液流变学及临床疗效的作用。方法 60例尘肺肺心病患者,随机分为治疗组(31例)和对照组(29例)。对照组按常规方法治疗,治疗组在常规治疗基础上加用低分子肝素针,观察2组临床疗效、肺功能[1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]、肺动脉平均压(mPAP)、血液流变学(全血黏度、红细胞压积、纤维蛋白原)等指标的变化。结果低分子肝素能缓解尘肺肺心病患者临床症状,改善肺功能和血液高凝,降低肺动脉高压;治疗后2组的治疗有效率、FEV1、FVC、FEV1/FVC、mPAP及全血黏度、红细胞压积、纤维蛋白原指标比较,差异均有统计学意义(P<0.05)。结论低分子肝素对肺心病肺动脉高压患者具有良好的治疗作用。
Objective To investigate the effect of low molecular weight heparin on hemorheology and clinical efficacy in patients with pneumoconiosis. Methods Sixty patients with pneumoconiosis were randomly divided into treatment group (n = 31) and control group (n = 29). The control group was treated by conventional method. The treatment group was given low molecular weight heparin needle on the basis of routine treatment. The clinical curative effect, pulmonary function [FEV1, FVC, FEV1 / FVC] , Mean pulmonary artery pressure (mPAP), hemorheology (whole blood viscosity, hematocrit, fibrinogen) and other indicators of change. Results Low molecular weight heparin could alleviate the clinical symptoms, improve pulmonary function and blood hypercoagulability in patients with pneumoconiosis and pulmonary disease, reduce the pulmonary hypertension. After treatment, the effective rate of treatment, FEV1, FVC, FEV1 / FVC, mPAP and whole blood viscosity, Plot, fibrinogen indicators, the differences were statistically significant (P <0.05). Conclusion Low molecular weight heparin has a good therapeutic effect on pulmonary heart disease patients with pulmonary hypertension.